{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:05:40Z","timestamp":1776938740240,"version":"3.51.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T00:00:00Z","timestamp":1608336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Cancer Center Research and Development Funds","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The clinical outcome of BRAF-mutated advanced melanoma has been improved by both molecular targeted therapies and immune checkpoint inhibitors. Long-term follow-up data reveal durable clinical responses in patients receiving first-line combinations of BRAF inhibitors plus MEK inhibitors, particularly those showing a complete response. Clinical outcomes are also associated with the lactate dehydrogenase levels and the number of metastatic organs. Although brain metastasis is frequently difficult to control, systemic therapy is preferred in cases with small and asymptomatic brain metastases associated with progressive extra-cranial disease. Control of intra-cranial disease with BRAF inhibitors plus MEK inhibitors is comparable with that of immune checkpoint inhibitors, although immune checkpoint inhibitors are superior to targeted therapies with respect to survival. The BRAF inhibitors plus MEK inhibitors regimen is well-tolerated, and toxicities are usually manageable and reversible, but differ according to the specific regimen used. Guidelines in the United States, Europe, and Japan recommend targeted therapy for patients who need early tumor responses. A meta-analysis of retrospective data shows that the baseline lactate dehydrogenase level is significantly higher in patients treated with BRAF inhibitors plus MEK inhibitors than in those treated with immune checkpoint inhibitors, suggesting that clinicians tend to use BRAF inhibitors plus MEK inhibitors for more advanced disease. Since there is insufficient efficacy and safety data on the use of targeted therapies for acral and mucosal melanoma, a retrospective analysis may be useful. The combination of molecular targeted therapy plus immune checkpoint inhibitors is expected to elicit further improvement. The results of several trials using combination or sequential therapies will be available in the next few years.<\/jats:p>","DOI":"10.1093\/jjco\/hyaa222","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T16:16:52Z","timestamp":1608308212000},"page":"315-320","source":"Crossref","is-referenced-by-count":5,"title":["Recent advances in molecular targeted therapy for unresectable and metastatic <i>BRAF<\/i>-mutated melanoma"],"prefix":"10.1093","volume":"51","author":[{"given":"Yukiko","family":"Kiniwa","sequence":"first","affiliation":[{"name":"Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuhei","family":"Okuyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,19]]},"reference":[{"key":"2021030800240814700_ref1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med."},{"key":"2021030800240814700_ref2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with Dabrafenib plus Trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med."},{"key":"2021030800240814700_ref3","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cam4.2110","article-title":"Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma","volume":"8","author":"Fujisawa","year":"2019","journal-title":"Cancer Med."},{"key":"2021030800240814700_ref4","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","article-title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients","volume":"31","author":"Nakamura","year":"2020","journal-title":"Ann Oncol"},{"key":"2021030800240814700_ref5","volume-title":"Genomic landscape of melanoma","author":"Bastian","year":"2018","edition":"4th"},{"key":"2021030800240814700_ref6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdermsci.2015.07.012","article-title":"Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients","volume":"80","author":"Sakaizawa","year":"2015","journal-title":"J Dermatol Sci."},{"key":"2021030800240814700_ref7","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat Commun"},{"key":"2021030800240814700_ref8","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/jnci\/djz005","article-title":"Targeted genomic profiling of Acral melanoma","volume":"111","author":"Yeh","year":"2019","journal-title":"J Natl Cancer Inst."},{"key":"2021030800240814700_ref9","volume-title":"Guideline of Drug Therapy for Melanoma, version 1","author":"Yamazaki","year":"2019"},{"key":"2021030800240814700_ref10","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol."},{"key":"2021030800240814700_ref11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/1346-8138.14210","article-title":"Phase 1\/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma","volume":"45","author":"Yamazaki","year":"2018","journal-title":"J Dermatol."},{"key":"2021030800240814700_ref12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving Dabrafenib combined with Trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol."},{"key":"2021030800240814700_ref13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med."},{"key":"2021030800240814700_ref14","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/1346-8138.15479","article-title":"Frequent brain metastases during treatment with BRAF\/MEK inhibitors: a retrospective single institutional study","volume":"47","author":"Nakamura","year":"2020","journal-title":"J Dermatol."},{"key":"2021030800240814700_ref15","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","article-title":"Phase I dose-escalation and -expansion study of the BRAF inhibitor Encorafenib (LGX818) in metastatic BRAF-mutant melanoma","volume":"23","author":"Delord","year":"2017","journal-title":"Clin Cancer Res."},{"key":"2021030800240814700_ref16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.10012","article-title":"Update on overall survival in COLUMBUS: a randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. (2020 ASCO annual meeting #10012)","volume":"38","author":"Gogas","year":"2020","journal-title":"J Clin Oncol."},{"key":"2021030800240814700_ref17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur J Cancer."},{"key":"2021030800240814700_ref18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021030800240814700_ref19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol."},{"key":"2021030800240814700_ref20","doi-asserted-by":"crossref","first-page":"e1197","DOI":"10.1634\/theoncologist.2018-0876","article-title":"Comprehensive clinical trial data summation for BRAF-MEK inhibition and checkpoint immunotherapy in metastatic melanoma","volume":"24","author":"Luke","year":"2019","journal-title":"Oncologist."},{"key":"2021030800240814700_ref21","doi-asserted-by":"crossref","first-page":"7637","DOI":"10.1002\/cam4.2625","article-title":"Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF\/MEK inhibitors, anti-PD-1 antibodies, or nivolumab\/ipilimumab","volume":"8","author":"Moser","year":"2019","journal-title":"Cancer Med."},{"key":"2021030800240814700_ref22","first-page":"52","article-title":"Dabrafenib plus trametinib for compassionate use in metastatic melanoma","volume":"96","author":"Algarra","year":"2017","journal-title":"Medicine."},{"key":"2021030800240814700_ref23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/1346-8138.15204","article-title":"Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma","volume":"47","author":"Takahashi","year":"2020","journal-title":"J Dermatol."},{"key":"2021030800240814700_ref24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"2021030800240814700_ref25","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"key":"2021030800240814700_ref26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"2021030800240814700_ref27","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol."},{"key":"2021030800240814700_ref28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12094-017-1706-2","article-title":"Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan","volume":"20","author":"Uhara","year":"2018","journal-title":"Clin Transl Oncol."},{"key":"2021030800240814700_ref29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/1346-8138.15151","article-title":"Japanese dermatological association guidelines: outlines of guidelines for cutaneous melanoma 2019","volume":"47","author":"Nakamura","year":"2020","journal-title":"J Dermatol."},{"key":"2021030800240814700_ref30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246191","article-title":"Intra- and inter-tumor BRAF heterogeneity in Acral melanoma: an immunohistochemical analysis","volume":"20","author":"Ito","year":"2019","journal-title":"Int J Mol Sci."},{"key":"2021030800240814700_ref31","article-title":"BRAF mutation heterogeneity in melanoma lesions","volume":"100","author":"Sakaizawa","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2021030800240814700_ref32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2017.05.015","article-title":"Discrepancy in BRAF status among patients with metastatic malignant melanoma: a meta-analysis","volume":"81","author":"Valachis","year":"2017","journal-title":"Eur J Cancer."},{"key":"2021030800240814700_ref33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230136","article-title":"BRAF V600E mutational load as a prognosis biomarker in malignant melanoma","volume":"15","author":"Sevilla","year":"2020","journal-title":"PLoS One."},{"key":"2021030800240814700_ref34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030690","article-title":"Immunohistochemical BRAF V600E expression and Intratumor BRAF V600E heterogeneity in Acral melanoma: implication in melanoma-specific survival","volume":"9","author":"Ito","year":"2020","journal-title":"J Clin Med."},{"key":"2021030800240814700_ref35","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/S0140-6736(20)31285-X","article-title":"Triple therapy for BRAF(V600)-mutated melanoma","volume":"395","author":"Ribas","year":"2020","journal-title":"Lancet."},{"key":"2021030800240814700_ref36","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","volume":"25","author":"Ascierto","year":"2019","journal-title":"Nat Med."},{"key":"2021030800240814700_ref37","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet."}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/3\/315\/36446291\/hyaa222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/3\/315\/36446291\/hyaa222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:24:46Z","timestamp":1615163086000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/3\/315\/6041786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,19]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,19]]},"published-print":{"date-parts":[[2021,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa222","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2020,12,19]]}}}